1
As filed with the Securities and Exchange Commission on November 4,December 8, 1998
Registration No. 333-66297
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------------
Amendment No. 1
toAMENDMENT NO. 2
TO
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
---------------------------
PRECISION OPTICS CORPORATION, INC.
(Exact name of Registrant as specified in its charter)
MASSACHUSETTS 04-2795294
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
---------------------------
22 East Broadway
Gardner, Massachusetts 01440
(978) 630-1800
(Address, including zip code, and telephone number, including area code, of
Registrant's principal executive offices)(ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF
REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES)
JACK P. DREIMILLER Copy to:
Senior Vice President, FinanceCOPY TO:
SENIOR VICE PRESIDENT, FINANCE EDWARD A. BENJAMIN, ESQUIRE
and Chief Financial OfficerAND CHIEF FINANCIAL OFFICER ROPES & GRAY
PRECISION OPTICS CORPORATION One International Place
22 East Broadway Boston, MA 02110-2624
Gardner, Massachusetts 01440 (617) 951-7434
(978) 630-1800
(Name, address, including zip code, and telephone number, including area code,
of agent for service)
---------------------------
Approximate date of commencement of proposed sale to the public: From time to
time after the effectiveness of the Registration Statement.
If the only securities being registered on this form are being offered pursuant
to dividend or interest reinvestment plans, please check the following box. [ ]
If any of the securities being registered on this form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. [X]
If this form is filed to register additional securities for an offering pursuant
to Rule 462(b) under the Securities Act, please check the following box and list
the Securities Act registration statement number of the earlier effective
registration statement for the same offering. [ ] ________
If this form is a post-effective amendment filed pursuant to Rule 462(c) under
the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ] _____________
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
CALCULATION OF REGISTRATION FEE
- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Title of Shares Amount to be Proposed Maximum Proposed Maximum Amount of
to be Registered Registered Offering Price Per Aggregate Offering Registration Fee
Share (1) Price (1)
- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Common Stock - $.01 Par Value 1,086,900 $1.375 $1,494,488 $416
- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
(1) Estimated, pursuant to Rule 457(c), solely for purposes of calculating
the registration fee based on the average of the high and low sales
prices of the Registrant's Common Stock on October 27, 1998 as reported
on the Nasdaq SmallCap Market, which date is within five business days
of the date of this Registration Statement.
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES
AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE
A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT
SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE
SECURITIES ACT OF 1933, OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING
PURSUANT TO SAID SECTION 8(a), MAY DETERMINE.
2
The information in this prospectus is not complete and may be changed. The
selling stockholders may not sell the Common Stock covered by this prospectus
until the registration statement filed with the Securities and Exchange
Commission is effective. This prospectus is not an offer to sell stock and it is
not soliciting an offer to buy stock in any state where an offer and sale is not
permitted.THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. THE
SELLING STOCKHOLDERS MAY NOT SELL THE COMMON STOCK COVERED BY THIS PROSPECTUS
UNTIL THE REGISTRATION STATEMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL STOCK AND IT IS
NOT SOLICITING AN OFFER TO BUY STOCK IN ANY STATE WHERE AN OFFER AND SALE IS NOT
PERMITTED.
- --------------------------------------------------------------------------------
PROSPECTUS Subject to Completion
November 4,SUBJECT TO COMPLETION
DECEMBER 8, 1998
PRECISION OPTICS CORPORATION, INC.
22 East Broadway
Gardner, Massachusetts 01440
(978) 630-1800
-----------------
We design, develop, manufacture and sell specialized optical systemsa variety of products that
make use of sophisticated lenses, prisms, mirrors and componentsother devices that detect
and optical thin film coatings. Ourtransmit light and visual images. our products include:
- arthroscopes, which are used in joint surgery;
- laryngoscopes, which are used in the diagnosis of
diseases of the throat;
- laparoscopes, which are used in abdominal surgery;
and
services include
medical products- stereo endoscopes, which are currently being tested
for use by hospitals and physicians, advanced optical products
and thin films and advanced optical system design and development services.in heart surgery.
In addition, we are currently developing a filter component for a device
designed to increase the amount of data that can be transmitted over fiber optic
cable lines.
Our principal executive offices are located at 22 East Broadway,
Gardner, Massachusetts 01440 and our phone number is (978) 630-1800.
The persons listed as "selling stockholders" on page 7 of this
prospectus are using the prospectus to offer for sale a total of 1,086,900
shares of our Common Stock. We will not receive any of the proceeds of this
offering.
Our Common Stock is traded on the NASDAQ SmallCap Market under the
symbol "POCI." On November 2,December 4, 1998, the last reported sale price of our Common
Stock was $1.25$0.97 per share.
An investment in our Common Stock involves a high degree of risk. You
should consider carefully the risk factors beginning on pageAN INVESTMENT IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. YOU
SHOULD CONSIDER CAREFULLY THE RISK FACTORS BEGINNING ON PAGE 2 of this
prospectus.OF THIS
PROSPECTUS.
---------------------------
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of the Common Stock covered by this
prospectus or determined if this prospectus is truthful or complete. Any
representation to the contrary is a criminal offense.NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THE COMMON STOCK COVERED BY THIS
PROSPECTUS OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
---------------------------
The date of this prospectus is __________, 1998
- --------------------------------------------------------------------------------
3
TABLE OF CONTENTS
Page
----
Risk Factors................................................................2Factors..................................................................2
Where You Can Find Additional Information...................................6Information.....................................6
Incorporation of Certain Documents By Reference.............................6Reference...............................6
Use of Proceeds. . . . . . .................................................6...................................................7
Selling Stockholders........................................................7Stockholders..........................................................7
Plan of Distribution........................................................8Distribution..........................................................8
Legal Matters...............................................................9
Experts.....................................................................9Matters.................................................................9
Experts.......................................................................9
RISK FACTORS
You should consider carefully the information contained in this section
of the prospectus in deciding whether to purchase shares of our Common Stock.YOU SHOULD CONSIDER CAREFULLY THE INFORMATION CONTAINED IN THIS SECTION
OF THE PROSPECTUS IN DECIDING WHETHER TO PURCHASE SHARES OF OUR COMMON STOCK.
In this prospectus, and from time to time in public statements made by
our management, we have made and will continue to make forward-looking
statements about our business, including predictions about our future financial
performance. Our actual results may differ significantly from the results
predicted in this prospectus and in future public statements. Factors that might
cause such a difference include, but are not limited to, the factors discussed
below:
Our Stock Faces Significant Price and Volume VolatilityOUR STOCK FACES SIGNIFICANT PRICE AND VOLUME VOLATILITY
Our Common Stock has had a public market since November 1990. The price
of our Common Stock has from time to time experienced significant price and
volume fluctuations. During calendar year 1998, for example, the market price of
our Common Stock decreased by 25% in one single trading day and increased by 31%
in another single trading day. The reasons for these fluctuations are sometimes
unrelated to our own operating performance. For instance, a competitor's product
failure or announcement of a new technology or product may have a significant
impact on the market price of our Common Stock. In addition, our Common Stock
periodically is the subject of limited trading activity and, as a result,
at timesinvestors may be
relatively illiquid.
The Success of Ourhave difficulty buying or selling our Common Stock on any given
trading day. During one four day period in calendar year 1997, for example, no
trading in our Common Stock took place on the Nasdaq SmallCap Market.
THE SUCCESS OF OUR WDM Initiative is Not GuaranteedINITIATIVE IS NOT GUARANTEED
We plan to devote the majority of our research and development
resources to the development and marketing of new products, particularly filters
made of specially treated glass which will be used as components in the
area of Wavelengthwavelength
Division Multiplexer (WDM) optical thin films. If
successfully developed, our WDM optical thin films will permit
telecommunications companies toMultiplexers (WDMS). WDMS are devices which, when inserted in fiber
optic cable lines, increase significantly the transmission capacityamount of fiber optic cable lines.data that such lines can
carry.
The Company is in the process of developing WDM thin filmfilter prototypes capable ofwhich
can reliably meetingmeet a strict set of operating specifications which
potential customers haveperformance requirements supplied to us.us by potential
customers. We cannot guarantee that these efforts will be successful or that we
will succeed in developing and marketing WDM thin
filmsfilters or any other new products.
Also, certain domestic and foreign companies have begun marketing products which
employ alternativetechnologies similar to our WDM technologies.filter technology. We cannot predict
whether our WDM products,filters, if and when successfully developed, will be perceived
in the marketplace as more cost-effective, efficient andor reliable than these
competing products.
2
4
Based upon our expectations about market acceptance of our WDM products,filters,
we expect to continue to increase our research and development expenditures in
the WDM area. Our operating results may be severely impaired if these
development efforts are unsuccessful or if sales of our new products are below
expectations.
We Rely Upon the Talents of a Few Key PersonsWE RELY HEAVILY UPON THE TALENTS OF OUR CHIEF EXECUTIVE OFFICER AND OUR VICE
PRESIDENT, OPERATIONS
Our performance depends to a large extent on a small number of key
scientific, technical, managerial, and marketing personnel. In particular, we
believe our success is highly dependent upon the services and reputation of both
our Chief Executive Officer, Mr. Richard E. Forkey and our Vice President,
Operations, Mr. Kumar M. Khajurivala. Loss of either Mr. Forkey's or Mr.
Khajurivala's services and scientific contributions could severely damage our
business.
We Must Continue to be Able to Attract Highly Skilled EmployeesWE MUST CONTINUE TO BE ABLE TO ATTRACT EMPLOYEES WITH THE SCIENTIFIC AND
TECHNICAL SKILLS THAT OUR BUSINESS REQUIRES
Our ability to attract employees with a high degree of scientific and
technical talent is crucial to the success of our business. There is intense
competition for the services of such persons, and we cannot guarantee that we
will be able to attract and retain individuals possessing the necessary
qualifications.
We Are Currently Incurring Net Operating LossesWE ARE CURRENTLY INCURRING NET OPERATING LOSSES
We have incurred net operating losses in each of the last six quarterly
periods ending June 30, 1998. These net operating losses totaled approximately
$2,725,000 during this eighteen-month period, and we have an accumulated deficit
of approximately $2,132,000 at June 30, 1998.
We attribute these recent losses largely to our transition away from
night vision products and services sold primarily under contracts or
subcontracts with the United States Government, and our concentration of
research and product development resources on new products, principally WDM
optical thin films.filters
for Wavelength Division Multiplexers (WDMS). Our WDM productsfilters are still in
development and have not yet resulted in appreciable revenues. Given the
uncertainties surrounding the development and marketing of our WDM products,filters, it
remains to be seen whether we will achieve profitability as a result of our
initiatives in the WDM area.
Our Quarterly Financial Results May FluctuateOUR QUARTERLY FINANCIAL RESULTS DEPEND ON A LARGE NUMBER OF FACTORS AND
THEREFORE MAY VARY QUARTER TO QUARTER
Our quarterly operating results may vary significantly depending upon
factors such as:
- the timing of completion of significant orders
- the timing and amount of our research and development
expenditures
- the costs of initial product production in connection with new
products
- the timing of new product introductions -- both by us and by
our competitors
- the timing and level of market acceptance of new products or
enhanced versions of our existing products
We cannot be certain whether we will be able to grow or sustain revenues or
achieve or maintain profitability on a quarterly or annual basis or that levels
of revenue and/or profitability may not vary from one such period to another.
3
5
We Operate in a Highly Competitive EnvironmentWE HAVE A NUMBER OF LARGE, WELL-FINANCED COMPETITORS
The industries in which we compete are highly competitive. Many of our
existing and potential competitors have greater financial resources and
manufacturing capabilities, more established and larger marketing and sales
organizations and larger technical staffs than we have. Other companies, some
with greater experience in the telecommunications, optics, semiconductor or
medical products industries, are seeking to produce products and services that
compete with our products and services.
We Depend to a Large Extent on a Small Group of Customers
Revenues fromWE HAVE LOST TWO SIGNIFICANT CUSTOMERS IN RECENT YEARS
In the fiscal year ended June 30, 1998, our three largest customers
wererepresented approximately 22%, 14% and 10%, respectively, of our total revenues forrevenues.
In the fiscal year ended June 30, 1998, and revenues from1997, our two largest customers wererepresented
approximately 38% and 23%, respectively, of our total revenues for the fiscal year ended June 30, 1997.revenues. No other
customerscustomer accounted for more than 10% of our revenues during those periods.
Two of the customers described above (one representing 22% of 1998
revenues and 38% of 1997 revenues and one representing 23% of 1997 revenues) no
longer place orders with us. We Are Subjectattribute the loss of their business to two
primary factors: declining demand for their own products (of which our products
were components) and the availability to those customers of lower cost
alternatives to our products sold by foreign manufacturers.
In the future, a High Degreesmall number of Regulatory Oversightcustomers may continue to represent a
significant portion of our total revenues in any given period. We cannot be
certain that such customers will consistently purchase our products at any
particular rate over any subsequent period.
WE ARE SUBJECT TO A HIGH DEGREE OF REGULATORY OVERSIGHT
The FDA has determined that we mayallowed us to market our currently existingthe medical products that arewe currently being soldsell
in the United States. However, prior FDA approval may be required before we can
market additional medical products that we may develop in the future. We may
also seek to sell current or future medical products in a manner that requires
us to obtain FDA permission to market such products. We may also require the
regulatory approval or license of other federal, state or local agencies or
comparable agencies in other countries.
We cannot be certain that we will continue to receive the FDA's
permission to market our current products or obtain the necessary regulatory
permission, approvals or licenses for the marketing of any of our future
products. Also, we cannot predict the impact on our business of FDA regulations
or determinations arising from future legislation or administrative action.
We Face Risks Inherent in Product Development and Production Under Fixed Price
ContractsWE FACE RISKS INHERENT IN PRODUCT DEVELOPMENT AND PRODUCTION UNDER FIXED PRICE
CONTRACTS
A significant portion of our business has been and may continue to be
devoted to research,
development and production of optical systems for customers
under fixed price contracts. For our purposes, a
fixed price contract is any contract under which we will provide products or
services for a fixed price over an extended period of time (usually six months
to a year, with some government contracts extending as long as three years). In
our 1998, 1997 and 1996 fiscal years, fixed price contracts represented
approximately 55%, 67% and 63%, respectively, of our total revenues. We expect
that revenues from fixed price contracts will continue to represent a
significant portion of our total revenues in future fiscal years.
Because they involve performance over time, we cannot predict with
certainty the expenses involved in meeting our obligations under such contracts, and therefore cannotfixed price
contracts. Therefore, we can never be sure at the time we enter into any single
fixed price contract that such contract will be profitable for us. Our Intellectual Property is SubjectAlthough
fixed price contracts were profitable for us overall in each of 1998, 1997 and
1996, cost
4
6
overruns have caused, and will likely continue to Infringement by Third Partiescause, individual fixed price
contracts that we enter into from time to time to be unprofitable.
THIRD PARTIES MAY INFRINGE ON OUR PATENTS
We hold a number of patents that are important to our business.
Although we are not currently aware of any past or present infringements of our
patents, we plan to protect these patents from infringement and obtain
additional patents whenever feasible. To this end, we have obtained
confidentiality agreements from our employees and consultants and others who
have access to the design of our products and other proprietary information.
Protecting and obtaining patents, however, is both time consuming and expensive.
We therefore may not have the resources necessary to assert all potential patent
infringement claims or pursue all patents that might be available to us.
4
6
We May Be Subject to Claims of Patent InfringementTHIRD PARTIES MAY CLAIM THAT WE HAVE INFRINGED ON THEIR PATENTS
The technologies used or to be used in our advanced optical systems may
infringe upon patents or proprietary technology held or owned by other persons.
Should these persons claim a proprietary right to all or part of any technology
that we use in our products, such a claim, regardless of its merit, could
involve us in costly litigation. If successful, such a claim could also result
in us being unable to freely to use the technology that was the subject of the
claim, or sell products embodying such technology.
We Depend on the Availability of Certain Key Supplies and ServicesWE DEPEND ON THE AVAILABILITY OF CERTAIN KEY SUPPLIES AND SERVICES
Certain key supplies used in our products, includingparticularly precision grade
optical glass, are available from only a few sources, each of which is located
outside the United States. Also, outside vendors grind and polish certain of our
lenses and other optical components, such as prisms and windows. Based upon our
ordering experience to date, we believe the materials and services required for
the production of our products are currently available in sufficient quantities.
Our requirements are small relative to the total supply, and we are not
currently encountering problems with availability. However, this does not mean
that we will continue to have timely access to adequate supplies of essential
materials and services in the future or that supplies of these materials and
services will be available on satisfactory terms when the need arises. Our
business could be severely damaged if we become unable to procure essential
materials and services in adequate quantities and at acceptable prices.
From time to time, certain of our products may be produced for us by
subcontractors, and our business is subject to the risk that these
subcontractors fail to make timely delivery. Our products and services are also
from time to time used as components of the products and services of other
manufacturers. We are therefore subject to the risk that manufacturers that
integrate our products or services into their own products or services are
unable to acquire essential supplies and services from third parties in a timely
fashion.
We May Require Additional FacilitiesSPACE CONSTRAINTS MAY REQUIRE US TO OBTAIN ADDITIONAL FACILITIES
We believe our current facilities are adequate for our existing
operations. However, we may require additional space if we significantly
increase production, acquire substantial new equipment, begin to produce
materials or supplies that we currently purchase from others or otherwise expand
our manufacturing capabilities. Any acquisition of additional facilities could
require us to make significant expenditures.
We Are Exposed To Product Liability Claims and Uninsured RisksOUR CUSTOMERS MAY CLAIM THAT THE PRODUCTS WE SOLD THEM WERE DEFECTIVE
Like any manufacturer, we are and always have been exposed to liability
claims resulting from the use of our products. We maintain product liability
insurance to cover us in the event of liability
5
7
claims, and no such claims have been asserted or threatened against us to date.
However, we cannot be certain that our insurance will be sufficient to cover all
possible future product liabilities.
We Are Subject to Environmental RegulationWE WOULD BE LIABLE IF OUR BUSINESS OPERATIONS HARMED THE ENVIRONMENT
Our operations are subject to a variety of federal, state and local
laws and regulations relating to the protection of the environment. From time to
time, we use hazardous materials in our operations. Although we believe that we
are in compliance with all applicable environmental laws and regulations, our
business could be severely damaged by any failure to maintain such compliance.
5
7
WHERE YOU CAN FIND ADDITIONAL INFORMATION
We are subject to the reporting requirements of the Securities Exchange
Act of 1934. This Act requires us to file annual and quarterly reports on our
financial and business results, proxy materials and other information with the
SEC. Our annual and quarterly reports, proxy statements and other information
can be inspected and copied at the SEC's Public Reference Room at 450 Fifth
Street, N.W., Washington, D.C. 20549. The public may obtain information on the
operation of the Public Reference Room by calling the Commission at
1-800-SEC-0330. In addition, the Commission maintains a web site (at
http://www.sec.gov) that contains reports, proxy and information statements, and
other information regarding issuers (including Precision Optics Corporation)
that file electronically with the SEC.
We have filed with the SEC a registration statement on Form S-3
covering the shares of Common Stock offered with this prospectus. This
prospectus does not contain all information contained in the registration
statement, certain parts of which are omitted in accordance with the SEC's rules
and regulations .regulations. Statements made in this prospectus as to the contents of any
other document (including exhibits to the registration statement) are not
necessarily complete. You should review the document itself for a thorough
understanding of its contents. The registration statement (including exhibits to
the registration statement) may be inspected and copied at the SEC's Public
Reference Room .Room. Also, the registration statement was filed electronically with
the SEC and is available on the SEC's web site (at http://www.sec.gov).
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
We have filedThe sec allows us to "incorporate by reference" the following documentsinformation we file
with the SEC. Each of these
documents isthem, which means that we can disclose important information to you by
referring you to those documents. The information incorporated by reference in , and is
an importantconsidered to be part of this prospectus:prospectus, and later information filed with the
SEC will update and supersede this information. We incorporate by reference the
documents listed below and any future filings made with the SEC under Sections
13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934 until our
offering is completed.
(i) Our annual report on Form 10-KSB for the fiscal year ended
June 30, 1998, including portions of our Proxy Statement dated
October 14, 1998, relating to our 1998 Annual Meeting of
Stockholders.Stockholders (SEC File No. 001-10647).
(ii) The description of our Common Stock contained in our
registration statement on Form S-1 (SEC File No. 33-43929.
All documents which we file with33-43929).
(iii) Our Quarterly report on Form 10-QSB for the SEC (i) after the date of filing
of the registration statement and prior to the effectiveness of the registration
statement and (ii) after the date of this prospectus and prior to the
termination of this offering shall be treated as part of this prospectus.fiscal quarter
ended September 30, 1998 (SEC File No. 001-10647).
We will provide, upon written or oral request, without charge, to each
person, including any beneficial owner, to whom a copy of this prospectus has
been delivered, a copy of any or all of the
6
8
documents which have been or may be incorporated in this prospectus by
reference, other than certain exhibits to such documents. Requests for such
copies should be directed to: Jack P. Dreimiller, Precision Optics Corporation,
Inc., 22 East Broadway, Gardner, Massachusetts 01440, (978) 630-1800.630- 1800.
USE OF PROCEEDS
We will not receive any of the proceeds of the Common Stock offered by
this prospectus.
6
8
SELLING STOCKHOLDERS
The following table sets forth certain information regarding the
ownership of our Common Stock by the selling stockholders as of September 30,December 4,
1998, including the number of shares of Common Stock offered with this
prospectus.
Shares of Common
Number of Shares Number of Shares Stock Beneficially
of Common Stock of Common Stock Owned After Offering
Beneficially Owned Offered with ------------------------------------------
Selling Stockholder Prior to Offering(1) this Prospectus Number Percent
------------------- -------------------- --------------------------------- ------ ------- ------
Special Situations Private Equity Fund, L.P. 750,000(2) 750,000 -0- **
c/o Special Situations Fund III, L.P.
153 East 53rd Street
New York, NY 10022
Special Situations Technology Fund, L.P. 250,000(3) 250,000 -0- **
c/o Special Situations of Fund III, L.P.
153 East 53rd Street
New York, NY 10022
Nathan Newman 69,09584,095 28,500(4) 40,59555,595 **
c/o Equity Securities Investments, Inc.
5353 Wayzata Boulevard, Suite 600
St. Louis Park, MN 55416
Peter L. Hauser 198,000 14,000(4) 184,000 2.76%
c/o Equity Securities Investments, Inc.
5353 Wayzata Boulevard, Suite 600
St. Louis Park, MN 55416
Ralph Murphy 25,400 5,000(4) 20,400 **
278 Dakota Street
Prescott, WI 54021
Leighton C. Natt 16,100 4,500(4) 11,600 **
3 Point Road
Bayport, MN 55003
Holderness Leasing, Inc. 135,650140,650 34,900(4) 100,750 1.50%105,750 1.58%
c/o Helmar Nielson
1530 Queens Boulevard, #301
Charlotte, NC 28207
- ------------------------------
** The number of shares indicated does not exceed one percent of the
number of shares of our Common Stock outstanding.
7
9
(1) Beneficial ownership is determined in accordance with the rules of the
SEC. In computing the number of shares beneficially owned by a person
and the percentage ownership of that person, shares of Common Stock
subject to warrants held by that person that are currently exercisable
or exercisable within 60 days of the date of this prospectus are deemed
outstanding. Such shares, however, are not deemed outstanding for the
purposes of computing the percentage ownership of 7
9
each other person.
Except as indicated in the footnotes to this table and pursuant to
applicable community property laws, each selling stockholder named in
the table above has sole voting and investment power with respect to
the shares set forth opposite his or its name. Percentage beneficial
ownership is based on 6,677,595 shares of Common Stock outstanding as
of September 30,December 4, 1998.
(2) Includes 375,000 shares which may be acquired within 60 days of the
date of this prospectus upon the exercise of outstanding warrants owned
by Special Situations Private Equity Fund, L.P. All shares owned by
Special Situations Private Equity Fund, L.P. were issued, or are
issuable upon the exercise of warrants issued, to it in a private
placement on June 30, 1998. As part of the private placement
transaction, we agreed to file the registration statement which
includes this prospectus.
(3) Includes 125,000 shares which may be acquired within 60 days of the
date of this prospectus upon the exercise of outstanding warrants owned
by Special Situations Technology Fund, L.P. All shares owned by Special
Situations Technology Fund, L.P. were issued, or are issuable upon the
exercise of warrants issued, to it in the June 30, 1998 private
placement described in footnote (2).
(4) Represents shares issued, or issuable upon, exercise of our Initial
Public Offering Selling Agent Warrants issued on or about July 8, 1992
and amended on December 30, 1994 (the "IPO Warrants") and our Private
Placement Selling Agent Warrants issued on or about July 8, 1992 and
amended on December 30, 1994 (the "Private Placement Warrants"). Both
the IPO Warrants and the Private Placement Warrants provide that any
holder may require us to include shares received upon exercise of their
Warrants in certain registration statements that we file. The shares
indicated are being included in this registration statement at the
request of the selling stockholder pursuant to this provision.
PLAN OF DISTRIBUTION
The selling stockholders have not advised us of any specific plans for
the distribution of the shares of Common Stock covered by this prospectus. These
shares may be sold from time to time by the selling stockholders or their
successors in interest .interest. Such sales may be made in one or more transactions on
the Nasdaq SmallCap Market or otherwise, at prices and at terms then prevailing
or at prices related to the then current market price, or in negotiated
transactions. These sales may take one or more of the following forms:
- a "block" trade in which a broker or dealer will attempt to
sell the shares as an agent but may position and resell a
portion of the block as a principal to facilitate the
transaction;
- purchases by a broker or dealer as a principal and resale by
such broker or dealer for its own account ;account; and
- ordinary brokerage transactions and transactions in which the
broker solicits purchasers.
In effecting sales, brokers or dealers engaged by the selling stockholders may
arrange for other brokers or dealers to participate. Brokers or dealers will
receive commissions or discounts from selling stockholders (and, if they act as
agent for the purchaser, from the purchaser). These commissions
8
10
may, in certain situations, be negotiated and in excess of customary rates. Any
participating brokers or dealers and certain of the selling stockholders may be
deemed to be "underwriters" within the meaning
8
10 of the Securities Act of 1933 in
connection with such sales. In addition, any shares covered by this prospectus
which qualify for sale pursuant to Rule 144 under the Securities Act of 1933 may
be sold under Rule 144 rather than under this prospectus.
If we are notified by a selling stockholder that a material arrangement
has been entered into with a broker-dealer for the sale of shares through a
block trade, special offering, exchange distribution or secondary distribution,
or a purchase by a broker-dealer as a principal, a supplemental prospectus will
be filed listing:
- the name of each selling stockholder and of the participating
broker-dealers(s);
- the number of shares involved;
- the price at which such shares were sold;
- the commissions paid or discounts or concessions allowed to
such broker-dealer(s), where applicable; and
- other facts material to the transaction.
We have agreed to pay the cost of registering the shares covered by
this prospectus and the costs of preparing this prospectus and the registration
statement under which it is filed. These expenses are estimated to be
approximately $22,531.$30,416.
Precision Optics Corporation and the selling stockholders have agreed
to indemnify each other against certain liabilities, including liabilities
arising under the Securities Act of 1933.
We have agreed to use our best efforts to keep the registration
statement of which this prospectus is a part continuously effective until the
earlier of (i) two years from the date on which warrants now held by Special
Situations Private Equity Fund, L.P. and Special Situations Technology Fund,
L.P. have been exercised in full or (ii) such time as all of the shares now held
by Special Situations Private Equity Fund, L.P. and Special Situations
Technology Fund, L.P. have been sold.
LEGAL MATTERS
The validity of the shares of Common Stock being offered under the
prospectus will be passed upon for Precision Optics Corporation by Ropes & Gray,
Boston, Massachusetts.
EXPERTS
The financial statements incorporated in this prospectus by reference
to our Annual Report on Form 10-KSB for the fiscal year ended June 30, 1998 have
been audited by Arthur Andersen LLP, independent auditors, as stated in their
report.
[Remainder of this page intentionally left blank.]blank]
9
11
================================================================================
No dealer, sales person or other individual has been authorized to give
any information or make any representations in connection with this offering
other than those contained in this prospectus. If given or made, such
information or representations must not be relied upon as having been authorized
by Precision Optics Corporation, the selling stockholders or any underwriter.
This prospectus does not constitute an offer to sell, or a solicitation of any
offer to buy any shares of our Common Stock in any jurisdiction where, or to any
person to whom, it is unlawful to make such offer or solicitation. The delivery
of this prospectus at any time does not imply that information herein is correct
as of any time subsequent to its date.NO DEALER, SALES PERSON OR OTHER INDIVIDUAL HAS BEEN AUTHORIZED TO GIVE
ANY INFORMATION OR MAKE ANY REPRESENTATIONS IN CONNECTION WITH THIS OFFERING
OTHER THAN THOSE CONTAINED IN THIS PROSPECTUS. IF GIVEN OR MADE, SUCH
INFORMATION OR REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED
BY PRECISION OPTICS CORPORATION, THE SELLING STOCKHOLDERS OR ANY UNDERWRITER.
THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL, OR A SOLICITATION OF ANY
OFFER TO BUY ANY SHARES OF OUR COMMON STOCK IN ANY JURISDICTION WHERE, OR TO ANY
PERSON TO WHOM, IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION. THE DELIVERY
OF THIS PROSPECTUS AT ANY TIME DOES NOT IMPLY THAT INFORMATION HEREIN IS CORRECT
AS OF ANY TIME SUBSEQUENT TO ITS DATE.
------------
TABLE OF CONTENTS
Page
----
Risk Factors ........................................................... 2
Where You Can Find Additional Information .............................. 6
Incorporation of Certain Documents By Reference ........................ 6
Use of Proceeds ........................................................ 67
Selling Stockholders ................................................... 7
Plan of Distribution ................................................... 8
Legal Matters .......................................................... 9
Experts ................................................................ 9
================================================================================
================================================================================
1,086,900 Shares of Common Stock
PRECISION OPTICS CORPORATION, INC.
_____________, 1998
================================================================================
12
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ItemITEM 14. Other Expenses of Issuance and DistributionOTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The following is an itemization of the expenses incurred or expected to
be incurred by Precision Optics Corporation, Inc. (the "Company") in connection
with the offering described in this registration statement. No portion of such
expenses are expected to be borne by selling stockholders. (Items marked with an
asterisk (*) represent estimated expenses):
Registration Fee.......................................... $ 416.00
Printing Cost*............................................ $ 1,115.002,000.00
Legal Fees*............................................... $18,000.00$25,000.00
Accounting Fees*.......................................... $ 2,000.00
Miscellaneous*............................................ $ 1,000.00
----------
TOTAL*............................................... $22,531.00$30,416.00
==========
ItemITEM 15. Indemnification of Officers and DirectorsINDEMNIFICATION OF OFFICERS AND DIRECTORS
The Company is organized under the laws of The Commonwealth of
Massachusetts. The Massachusetts Business Corporation Law provides that
indemnification of directors, officers, employees and other agents of a
corporation, and persons who serve at its request as directors, officers,
employees or other agents of another organization, or who serve at its request
in any capacity with respect to any employee benefit plan, may be provided by
the corporation to whatever extent specified in or authorized by its articles of
organization, a by-law adopted by the stockholders or a vote adopted by the
holders of a majority of the shares of stock entitled to vote on the election of
directors, except that no indemnification may be provided for any person with
respect to any matter as to which the person shall have been adjudicated in any
proceeding not to have acted in good faith in the reasonable belief that his
action was in the best interest of the corporation. Under Massachusetts law, a
corporation can purchase and maintain insurance on behalf of any person against
liability incurred as a director, officer, employee, agent or person serving at
the request of the corporation as a director, officer, employee or other agent
of another organization or with respect to any employee benefit plan, in his
capacity as such, whether or not the corporation would have the power to itself
indemnify him against such liability.
The Company's articles of organization provide that its directors shall
not be liable to the Company or its stockholders for monetary damages for breach
of fiduciary duty as a director, except to the extent that exculpation from
liabilities is not permitted under the Massachusetts Business Corporation Law as
in effect at the time such liability is determined. The by-laws of the Company
provide generally that the Company shall, to the extent legally permissible,
indemnify its directors and officers against all liabilities and expenses
incurred by them in connection with the defense or disposition of any action,
suit or other proceeding in which he may be involved, or by which he may be
threatened, by reason of his being or having been a director or officer, except
with respect to any matter as to which he shall have been adjudicated in any
proceeding not to have acted in good faith in the reasonable belief that his
action was in the best interest of the Company. In addition, the Company holds a
directors and officers liability policy.
II-1
13
ItemITEM 16. ExhibitsEXHIBITS
The following exhibits are filed herewith:
Exhibit
No. Title
- ------- -----
2.1 Stock Subscription Agreement dated as of June 30, 1998 by and among
the Company, Special Situations Private Equity Fund, L.P. and
Special Situations Technology Fund, L.P. (1)
4.1 Articles of Organization of the Company (2)
4.2 By-laws of the Company (3)
4.3 Specimen Common Stock Certificate (2)
4.4 Registration Rights Agreement dated as of June 30, 1998 by and among
the Company, Special Situations Private Equity Fund, L.P. and
Special Situations Technology Fund, L.P. (1)
4.5 Common Stock Purchase Warrant dated June 30, 1998 issued to Special
Situations Private Equity Fund, L.P. (1)
4.6 Common Stock Purchase Warrant dated June 30, 1998 issued to Special
Situations Technology Fund, L.P. (2)
4.7 Sample Initial Public Offering Selling Agent Warrant dated December
30, 1994 (4)
4.8 Sample Private Placement Selling Agent Warrant dated December 30,
1994 (4)
5.1 Opinion of Ropes & Gray (4)
23.1 Consent of Arthur Andersen LLP
(4)
23.2 Consent of Ropes & Gray (4)
24.1 Power of Attorney (4)
27.1 Financial Data Schedule (4)
(1) Incorporated herein by reference to the Company's 1998
Annual Report on Form 10-KSB.
(2) Incorporated herein by reference to the Company's
Registration Statement on Form S-18 (No. 33-36710-B).
(3) Incorporated herein by reference to the Company's 1991
Annual Report on Form 10-KSB.
(4) Previously filed with the SEC on October 29, 1998.
II-2
14
ItemITEM 17. UndertakingsUNDERTAKINGS
(a) The Company hereby undertakes:
(1) to file, during any period in which offers or sales are being made,
a post-effective amendment to this registration statement;
(i) to include any prospectus required by section 10(a)(3) of
the Securities Act;
(ii) to reflect in the prospectus included within this
registration statement any facts or events arising after the effective
date of this registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a
fundamental change in the information set forth in this registration
statement;
(iii) to include any material information with respect to the
plan of distribution not previously disclosed in this registration
statement or any material change to such information in this
registration statement;
provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the
information required to be included in a post-effective amendment by those
paragraphs is contained in periodic reports filed with or furnished to the SEC
by the registrant pursuant to Section 13 or 15(d) of the Exchange Act that are
incorporated by reference in this registration statement.
(2) that, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to be a new
registration statement for the securities offered therein, and the offering of
such securities at that time shall be deemed to be the initial bona fide
offering thereof;
(3) to remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of
the offering; and
(4) that, insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons
of the registrant, the Company has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy
as expressed in the Securities Act and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other than the
payment by the Company of expenses incurred or paid by a director, officer or
controlling person of the Company in the successful defense of any action, suit
or proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the Company will, unless in the
opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue.
[Remainder of this page intentionally left blank]
II-3
15
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this Amendment
No. 12 to the Registration Statement on Form S-3 to be signed on its behalf by
the undersigned, thereunto duly authorized, in the Town of Gardner,
Massachusetts, on the 4th8th day of November,December, 1998.
PRECISION OPTICS CORPORATION, INC.
By: /s/ Richard E. Forkey
-----------------------------------------------------------------------
Richard E. Forkey
Chairman, Chief Executive
Officer and President
Pursuant to the requirements of the Securities Act of 1933, this
Amendment No. 12 to Registration Statement on Form S-3 has been signed by the
following persons in the capacities and on the dates indicated.
Signature Capacity Date
- --------- -------- ----
/s/ Richard E. Forkey Chairman of the November 4, 1998
- ------------------------ Board of Directors,
Richard E. Forkey Chief Executive Officer
and President
(principal executive officer)
/s/ Jack P. Dreimiller Senior Vice President, November 4, 1998
- ------------------------ Finance, Chief Financial
Jack P. Dreimiller Officer and Clerk (principal
financial and accounting
officer)
* Director November 4, 1998
- ------------------------
Edward A. Benjamin
* Director November 4, 1998
- ------------------------
H. Angus Macleod
* Director November 4, 1998
- ------------------------
Austin W. Marxe
* Director November 4, 1998
- ------------------------
16
Signature Capacity Date
- --------- -------- ----
/s/ Richard E. Forkey Chairman of the December 8, 1998
- --------------------------------- Board of Directors,
Richard E. Forkey Chief Executive Officer
and President
(principal executive officer)
/s/ Jack P. Dreimiller Senior Vice President, December 8, 1998
- ---------------------------------- Finance, Chief Financial
Jack P. Dreimiller Officer and Clerk (principal
financial and accounting
officer)
* Director December 8, 1998
- ----------------------------------
Edward A. Benjamin
* Director December 8, 1998
- ----------------------------------
H. Angus Macleod
* Director December 8, 1998
- ----------------------------------
Austin W. Marxe
* Director December 8, 1998
- ----------------------------------
Joel R. Pitlor
16
* Director November 4,December 8, 1998
- ----------------------------------------------------------
Robert R. Shannon
* By: /s/ Jack P. Dreimiller
---------------------------------------------------
Jack P. Dreimiller
Attorney-in-Fact